Medical University of South Carolina - Cancer Center Support Grant

南卡罗来纳医科大学 - 癌症中心支持补助金

• 批准号: 9338823
• 负责人: ANTHONY J ALBERG
• 金额: $ 10.47万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9338823
• 关键词: Academic Medical Centers; Address; Award; Biomedical Engineering; Biometry; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Immunology Science; Cells; Charge; Clinical; Clinical Trials; Communities; Coupling; Development; Diagnosis; Enrollment; Ensure; Extramural Activities; Funding; Goals; Head; Healthcare; Instruction; Leadership; Malignant Neoplasms; Medical; Minority; Mission; Molecular; Movement; NCI Center for Cancer Research; National Cancer Institute; Oncogenes; Patients; Regulation; Research; Resources; Rural Population; Scientist; Secure; Services; South Carolina; Technology; Therapeutic; Therapy Evaluation; Tissues; Translational Research; Translations; Underserved Population; Universities; anticancer research; authority; base; bench to bedside; biobank; cancer education; cellular imaging; college; drug discovery; innovation; interdisciplinary collaboration; medically underserved; molecular imaging; novel strategies; outreach; population based; programs; ranpirnase; rapid growth; research facility; treatment trial

The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase respectively since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft2 of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft2. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.

南卡罗来纳医科大学 (MUSC) 霍林斯癌症中心 (HCC) 寻求更新其 2009 年通过 P30 癌症中心支持拨款获得美国国家癌症研究所 (NCI) 称号 （CCSG）机制。作为南卡罗来纳州领先的学术医疗中心，MUSC 负责建立临床、基础、转化和基于人群的研究项目，以满足该州重大的医疗保健需求。 HCC 的使命是减轻南卡罗来纳州的癌症负担。为了完成这一使命，主任 Andrew S. Kraft 博士和 HCC 高级领导层建立了一个强大的跨学科基础，目前包括来自 5 个 MUSC 学院和 20 个学术部门的 122 名癌症科学家。 HCC 的四个项目推动了跨学科的创新研究：癌症基因与分子调控、癌症免疫学、发育性癌症治疗和癌症控制。共享研究资源支持快速发现和走向有效的转化研究，本申请中介绍了其中五个资源：脂质组学、细胞评估和治疗、细胞和分子成像、生物储存库和组织分析以及生物统计学。 HCC 还为其临床试验办公室寻求 CCSG 支持，该办公室在过去四年中带头将介入治疗试验的应计数量大幅增加了 59%。值得注意的是，2012 年参加介入治疗试验的患者中有 26% 是少数族裔，这意味着该项目期间增加了 45%。 HCC 领导的针对南卡罗来纳州的渐进式外展服务和癌症教育推动了这一目标，南卡罗来纳州人口主要是农村人口，其中包括一些美国医疗服务最匮乏的人群。如今，HCC 每年的外部研究经费总额为 4,080 万美元，其中 来自 NCI 的资金达 1,860 万美元，自 2009 年以来分别增长了 31% 和 54%。HCC 在第一个项目期间成功利用了 CCSG 资金及其 NCI 指定癌症中心的地位，以继续该中心的快速发展。在当前项目期间，HCC 支持该中心进行 34 名战略招聘。 MUSC 两个最先进的研究设施（生物工程和药物发现大楼）的启用，使 HCC 研究空间增加了 66,156 平方英尺，使 HCC 管理下的校园总空间达到 270,174 平方英尺。自 2009 年以来，HCC 已投资 530 万美元来引进尖端技术，并获得了另外 380 万美元的机构承诺，以扩大可用资源的范围。这些令人印象深刻的进展确保 HCC 科学家将继续保持他们的模范记录，为理解癌症生物学做出重大贡献，同时将这些发现与癌症控制、诊断和治疗的新方法的开发相结合。